B
VKTX icon

Bailard’s Viking Therapeutics VKTX Stock Holding History

Bailard’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-46,720
Closed -$272K – 688
2020
Q3 		$272K Sell
46,720
-260,480
-85% -$1.79M 0.01% 405
2020
Q2 		$2.21M Sell
307,200
-100,000
-25% -$664K 0.12% 132
2020
Q1 		$1.91M Buy
407,200
+137,700
+51% +$846K 0.14% 134
2019
Q4 		$2.16M Sell
269,500
-54,100
-17% -$394K 0.12% 148
2019
Q3 		$2.23M Buy
323,600
+6,000
+2% +$44.6K 0.13% 147
2019
Q2 		$2.64M Buy
317,600
+5,400
+2% +$46.1K 0.16% 125
2019
Q1 		$3.1M Buy
312,200
+163,200
+110% +$1.37M 0.19% 112
2018
Q4 		$1.14M Buy
+149,000
New +$1.78M 0.08% 199

Other funds holding VKTX

ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.47B AUM 86.42% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Fiera Capital (Canada)
Fiera Capital (Canada) Montreal, Quebec, Canada $27.6B AUM 23.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Bailard's VKTX Position: Q4 2020 in Review

Bailard sold out of Viking Therapeutics (VKTX) in Q4 2020, closing a stake of 46,720 shares — an estimated $272K sold.

Bailard first reported a position in VKTX in Q4 2018 and held it in 8 quarters. The position peaked at $3.1M in Q1 2019. 143 funds tracked by Wall St. Rank hold VKTX as of Q4 2020.

  • Bailard reported no remaining Viking Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Bailard sold 46,720 Viking Therapeutics shares in Q4 2020, an estimated $272K.
  • Bailard first reported a position in Viking Therapeutics in Q4 2018 and held it in 8 quarters.
  • Bailard's Viking Therapeutics position peaked at $3.1M in Q1 2019.
  • 143 funds tracked by Wall St. Rank held Viking Therapeutics as of Q4 2020.

Based on Bailard's 13F filing for Q4 2020, filed 3 Feb 2021.